Samer Al Hadidi, MD, MS

Associate Member

Research Program:

Cancer Therapeutics

Faculty Rank:

Assistant Professor

Campus:

University of Arkansas for Medical Sciences

College:

College of Medicine

Department:

Internal Med Hem-Onc

Cancer Research Interest

Disease Site Focus: Multiple Myeloma
Research Focus Area: Prevention, Treatment, Informatics, Detection, Diagnosis/ Prognosis
Type of Research: Clinical
Research Interest Statement: Dr. Al Hadidi research interests include plasma cell dyscrasias including multiple myeloma with a focus on drug development, cellular therapy, immunotherapy, health equity and medical education.

Contact Information

Email Address: SALHADIDI@UAMS.EDU
Profiles Research Networking Software: View Profile

Open Clinical Trials

“A Phase 1B, Open-label Study of Elranatamab in Combination with Carfilzomib Plus Dexamethasone and Elranatamab in Combination with PF-07901801 in Participants with Relapsed Refractory Multiple Myeloma” (NCT05675449)
“S2209, A Phase III Randomized Trial For Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail Or In A Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance” (NCT05561387)

Recent Publications

Cheng Y, Sun F, Alapat DV, [et al., including Hadidi SA]. Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages. Blood cancer journal. 2024 14(1):194. PMID: 39505839. PMCID: PMC11541562.
Mohyuddin GR, Mian H, Gayowsky A, [et al., including Al Hadidi S]. Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study. Blood cancer journal. 2024 14(1):181. PMID: 39414772. PMCID: PMC11484707.
Kakkilaya A, Trando A, Cliff ERS, [et al., including Al Hadidi S]. Evaluating early intervention in smoldering myeloma clinical trials: a systematic review. The oncologist. 2024. PMID: 39236068.
Akhtar OS, Szabo A, Bhatlapenumarthi V, [et al., including Al-Hadidi S]. Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies. British journal of haematology. 2024. PMID: 39192546.
Al Hadidi S, Ababneh O, Schinke C, [et al.]. Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma. American journal of hematology. 2024. PMID: 39109821.
Naqvi S, Shrestha A, Alzubi M, [et al., including Al Hadidi S]. Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab. EJHaem. 2024 5(4):789-792. PMID: 39157593. PMCID: PMC11327703.
Zureigat H, Adcock B, Nurse DP, [et al., including Al Hadidi S]. Navigating The 2022 International Consensus and World Health Organization Classifications of Hematopathology: A Call for Unified Diagnostic Language. Archives of pathology & laboratory medicine. 2024. PMID: 38952288.
Persaud S, Al Hadidi S, Anderson TS, [et al.]. Industry Payments to Physicians Endorsing Drugs and Devices on a Social Media Platform. JAMA. 2024 331(24):2131-2134. PMID: 38814636. PMCID: PMC11140571.
Patel TH, van Rhee F, Al Hadidi S. Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma. Clinical lymphoma, myeloma & leukemia. 2024. PMID: 39003099.
Patel T, Chen C, Al Hadidi S, [et al.]. Reflections and Roadmaps: Career Development Beyond the FDA-AACR Oncology Educational Fellowship. Clinical cancer research : an official journal of the American Association for Cancer Research. 2024. PMID: 38856702.
Altarawneh H, Manasrah M, Al Shanableh Y, [et al., including Al Hadidi S]. Authorship characteristics of hematology and oncology education chapters: A comprehensive analysis. Journal of cancer policy. 2024 40:100484. PMID: 38750724.
Shrestha A, Alzubi M, Alrawabdeh J, [et al., including Al Hadidi S]. B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma. EJHaem. 2024 5(3):554-559. PMID: 38895072. PMCID: PMC11182413.
Al Hadidi S, Heslop HE, Brenner MK, Suzuki M. Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies. Molecular therapy : the journal of the American Society of Gene Therapy. 2024. PMID: 38822527. PMCID: PMC11405165.
Elemian S, Al Hadidi S. Targeting GPRC5D in multiple myeloma. Expert review of anticancer therapy. 2024:1-10. PMID: 38607646.
Al Hadidi S. Clinical trials of T-cell re-directing therapy in plasma cell precursor conditions. European journal of cancer (Oxford, England : 1990). 2024 203:114045. PMID: 38604006.
Guo W, Strouse C, Mery D, [et al., including Al Hadidi S]. A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation. Cancers. 2024 16(6). PMID: 38539451. PMCID: PMC10969019.
Mohan M, Monge J, Shah N, [et al., including Al-Hadidi S]. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood cancer journal. 2024 14(1):35. PMID: 38443345. PMCID: PMC10914756.
Mohan M, Szabo A, Patwari A, [et al., including Hadidi SA]. Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma. Bone marrow transplantation. 2024. PMID: 38361116.
Guo W, Zhan Y, Mery D, [et al., including Hadidi SA]. Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems. Blood cancer journal. 2024 14(1):30. PMID: 38355688. PMCID: PMC10866867.
Sun F, Cheng Y, Wanchai V, [et al., including Al Hadidi S]. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nature communications. 2024 15(1):615. PMID: 38242888. PMCID: PMC10798961.
Patel N, Al Hadidi S, Yellapragada S. Pathophysiology and Treatments of Complications of Waldenström's Macroglobulinemia. Clinical hematology international. 2024 6(4):11-18. PMID: 39417016. PMCID: PMC11477924.
Patel TH, Bachu R, Shrivastava T, [et al., including Al Hadidi S]. Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. Clinical hematology international. 2024 6(3):54-60. PMID: 39345654. PMCID: PMC11428156.
Al Hadidi S, Ababneh O, Schinke C, [et al.]. Three Years Maintenance with VRD in Multiple Myeloma: Results of Total Therapy IIIB with a 15-Year Follow Up. Blood advances. 2023. PMID: 38052037. PMCID: PMC10845028.
Abusamak AA, Abusamak M, Al-Abbadi M, [et al., including Al Hadidi S]. Use of subjective minimizing language at hematology and oncology conferences: A systematic review. Journal of cancer policy. 2023 39:100461. PMID: 38061494.
Alrawabdeh J, Alzu'bi M, Alzyoud M, [et al., including Al Hadidi S]. Characteristics of Post-hoc Subgroup Analyses of Oncology Clinical Trials: A Systematic Review. JNCI cancer spectrum. 2023. PMID: 38006333. PMCID: PMC11025370.
Rafae A, van Rhee F, Al Hadidi S. Perspectives on the Treatment of Multiple Myeloma. The oncologist. 2023. PMID: 37995307. PMCID: PMC10911930.
Najjar M, McCarron J, Cliff ERS, [et al., including Al Hadidi S]. Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma. JAMA network open. 2023 6(11):e2342195. PMID: 37948080. PMCID: PMC10638643.
Sun F, Cheng Y, Chen JR, [et al., including Al Hadidi S]. BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. The Journal of clinical investigation. 2023. PMID: 37883186. PMCID: PMC10760955.
Cheng Y, Sun F, Alapat DV, [et al., including Al Hadidi S]. High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma. Cell reports. Medicine. 2023 4(10):101214. PMID: 37794587. PMCID: PMC10591052.
Hammons L, Szabo A, Janardan A, [et al., including Al Hadidi S]. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2023. PMID: 37646658. PMCID: PMC10905074.
Ali MO, Abdullah HM, Obeidat K, [et al., including Al Hadidi S]. Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review. EJHaem. 2023 4(3):719-722. PMID: 37601879. PMCID: PMC10435726.
Fahmawi S, Schinke C, Thanendrarajan S, [et al., including Al Hadidi S]. Under-representation of black patients with multiple myeloma in studies supporting International Myeloma Working Group guidelines. Journal of cancer policy. 2023 37:100433. PMID: 37468042.
Chakraborty R, Al Hadidi S. Intent Matters: Real-World Applicability of Idecabtagene Vicleucel Usage in the United States. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 41(20):3657-3658. PMID: 37235838.
Sun F, Cheng Y, Ying J, [et al., including Al Hadidi S]. A gene signature can predict risk of MGUS progressing to multiple myeloma. Journal of hematology & oncology. 2023 16(1):70. PMID: 37386588. PMCID: PMC10308756.
Mohan M, Gong Z, Ashby TC, [et al., including Al Hadidi S]. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. Cancer. 2023. PMID: 37282609.
Chakraborty R, Al Hadidi S, Cliff ERS, Mohyuddin GR. Is aggressive treatment of smoldering myeloma the path to curing myeloma?. Blood advances. 2023. PMID: 37196639. PMCID: PMC10405196.
Abu Za'nouneh FJ, Ababneh O, Schinke C, [et al., including Al Hadidi S]. Variability of definition of high-risk multiple myeloma across phase III clinical trials. EJHaem. 2023 4(2):454-458. PMID: 37206288. PMCID: PMC10188470.
Mazahreh F, Mazahreh L, Schinke C, [et al., including Al Hadidi SA]. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood advances. 2023. PMID: 36857755. PMCID: PMC10331406.
Mazahreh F, Al-Hader AA, Al Hadidi S. Visa Constraints and Career Choices for Oncologists. Journal of the National Comprehensive Cancer Network : JNCCN. 2023 21(3):332-334. PMID: 36898360.
Ragon BK, Shah MV, D'Souza A, [et al., including Al Hadidi SA]. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood advances. 2023. PMID: 36827681. PMCID: PMC10275699.
Al Hadidi S, Dongarwar D, Schinke C, [et al.]. Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma. Clinical hematology international. 2023. PMID: 36737587. PMCID: PMC10241736.
Al Hadidi S, Abu Zaid MI, Mustafa Ali M. Institutional disparities in the distribution of the American Society of Clinical Oncology grants. Journal of cancer policy. 2023 35:100404. PMID: 36649905.
Al Hadidi S, van Rhee F. Overall Survival Analysis of the Use of Elotuzumab in ELOQUENT-3 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023:JCO2202098. PMID: 36626704.
Al Hadidi S, Abuali I. The Inflation in Oncology Publications and Journals: A Vicious Cycle That Needs Immediate Attention. Cancer investigation. 2023:1-3. PMID: 36592137.
Hussain M, Khan F, Al Hadidi S. The use of bone-modifying agents in multiple myeloma. Blood reviews. 2023 57:100999. PMID: 36050125.
Shrivastava T, Van Rhee F, Al Hadidi S. Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives. OncoTargets and therapy. 2023 16:441-464. PMID: 37359353. PMCID: PMC10290473.
Hussain M, Yellapragada S, Al Hadidi S. Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article. Blood and lymphatic cancer : targets and therapy. 2023 13:33-57. PMID: 37731771. PMCID: PMC10508231.
Wu C, Dongarwar D, Al Hadidi S. Racial Disparities in Plasma Cell Leukemia Outcomes Among Hospitalized Patients in the United States. Clinical hematology international. 2023 5(4):1-9. PMID: 37752989. PMCID: PMC10515655.
Anampa-Guzmán A, Alam ST, Abuali I, Al Hadidi S. Health Disparities Experienced by Hispanic Americans with Multiple Myeloma: A Systematic Review. Clinical hematology international. 2022. PMID: 36586086. PMCID: PMC10063691.
Al Hadidi S, Cliff ERS. CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptor-T-cell therapy in multiple myeloma. European journal of cancer (Oxford, England : 1990). 2022 182:1-2. PMID: 36680878.
Al Hadidi S, Szabo A, Esselmann J, [et al.]. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone marrow transplantation. 2022. PMID: 36550200.
Sawalha L, Kelkar AH, Mohyuddin GR, [et al., including Al Hadidi S]. Analysis of repeated roles in editorial boards at oncology focused journals. Journal of cancer policy. 2022 35:100380. PMID: 36538988.
Etekal T, Koehn K, Sborov DW, [et al., including Al Hadidi S]. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. British journal of haematology. 2022. PMID: 36495317.
Mohan M, Rein LE, Thalambedu N, [et al., including Al Hadidi S]. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. American journal of hematology. 2022 97(12):E451-E453. PMID: 36097868.
Al Hadidi S, Dongarwar D, Salihu H, [et al.]. Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States. Clinical hematology international. 2022 4(3):117-120. PMID: 36131130. PMCID: PMC9492819.
Schinke C, Poos AM, Bauer MA, [et al., including Al Hadidi S]. Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level. Blood advances. 2022. PMID: 35977111. PMCID: PMC9647426.
Dweik A, Dweik H, Mian H, [et al., including Al Hadidi S]. Gender disparities in multiple myeloma publications. EJHaem. 2022 3(3):966-969. PMID: 36051049. PMCID: PMC9422002.
Alqazaqi R, Schinke C, Thanendrarajan S, [et al., including Al Hadidi S]. Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma. JAMA network open. 2022 5(8):e2228877. PMID: 36018590. PMCID: PMC9419017.
Fatoki RA, Koehn K, Kelkar A, [et al., including Al Hadidi S]. Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. JCO global oncology. 2022 8:e2200119. PMID: 35960904. PMCID: PMC9470137.
Syaj S, Al-Kraimeen L, Akhdar M, [et al., including Al Hadidi S]. Gender and early-career faculty disparities in hematology and oncology board review lecture series. Blood advances. 2022. PMID: 35894637. PMCID: PMC9791299.
Thalambedu N, Al Hadidi S. Thromboprophylaxis in multiple myeloma. Leukemia & lymphoma. 2022:1-9. PMID: 35759648.
Ali MO, Al Hadidi S. High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma. Transplantation and cellular therapy. 2022. PMID: 35750284.
Ababneh O, Abushukair H, Qarqash A, [et al., including Al Hadidi S]. The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia. Clinical hematology international. 2022 4(1-2):21-29. PMID: 35950210. PMCID: PMC9358782.
Al Hadidi S, Zangari M, van Rhee F. Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions. JAMA oncology. 2022. PMID: 35482363.
Mohan M, Becnel MR, Shah UA, [et al., including Al Hadidi S]. Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. American journal of hematology. 2022. PMID: 35472167. PMCID: PMC10476149.
Al Hadidi S, Schinke C, Thanendrarajan S, [et al.]. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms. JAMA network open. 2022 5(4):e228161. PMID: 35442451. PMCID: PMC9021907.
Hadidi SA. Melflufen in multiple myeloma: the conclusion matters. The Lancet. Haematology. 2022 9(4):e244. PMID: 35358437.
Abushukair H, Syaj S, Ababneh O, [et al., including Al Hadidi S]. First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis. American journal of hematology. 2022. PMID: 35358350.
Larsen K, Spencer H, Mohan M, [et al., including Al Hadidi S]. Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission. Journal of clinical medicine. 2022 11(6). PMID: 35329966. PMCID: PMC8955129.
Mohan M, Gundarlapalli S, Szabo A, [et al., including Al Hadidi S]. Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma. American journal of hematology. 2022. PMID: 35285981.
Al Hadidi S. The Use of Modified Surrogate End Points in Cancer Clinical Trials. Cancer investigation. 2021:1-3. PMID: 34775893.
Nanah A, Al Hadidi S. Bing-Neel Syndrome: Update on the Diagnosis and Treatment. Clinical lymphoma, myeloma & leukemia. 2021. PMID: 34674984.
Al Hadidi S, Kamble RT, Carrum G, [et al.]. Assessment and reporting of quality-of-life measures in pivotal clinical trials of hematological malignancies. Blood advances. 2021. PMID: 34461636. PMCID: PMC8759126.
Al Hadidi S, Yellapragada S. Treatment Options for Relapsed and Refractory Multiple Myeloma: A Luxury or a Challenge?. JAMA oncology. 2021. PMID: 34383000.
Al Hadidi S, Dongarwar D, Salihu HM, [et al.]. Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study. Leukemia & lymphoma. 2021:1-8. PMID: 34278937. PMCID: PMC8962656.
Al Hadidi S, Ramos CA. Level of evidence for FDA drug approvals in pivotal clinical trials of hematological malignancies. Leukemia & lymphoma. 2021 62(6):1522-1524. PMID: 33491524. PMCID: PMC8928596.
Awidi M, Al Hadidi S. Participation of Black Americans in Cancer Clinical Trials: Current Challenges and Proposed Solutions. JCO oncology practice. 2021 17(5):265-271. PMID: 33974816. PMCID: PMC8258017.
Caro J, Al Hadidi S, Usmani S, [et al.]. How to Treat High-Risk Myeloma at Diagnosis and Relapse. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2021 41:291-309. PMID: 34010042.
Al-Hadidi SA, Lee HJ. Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma. JCO oncology practice. 2021 17(2):64-71. PMID: 33434064. PMCID: PMC8258137.
Al-Hadidi SA, Chuang HH, Miranda RN, Lee HJ. Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma. Clinical lymphoma, myeloma & leukemia. 2021 21(2):e105-e111. PMID: 33160934. PMCID: PMC7878303.
Al Hadidi SA, Lee HJ. Pembrolizumab for the treatment of Hodgkin Lymphoma. Expert opinion on biological therapy. 2020 20(11):1275-1282. PMID: 33006479.
Al Hadidi S, Miller-Chism CN, Kamble R, Mims M. Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma. Clinical lymphoma, myeloma & leukemia. 2020 20(9):e579-e589. PMID: 32409106.
Al Hadidi S, Mims M, Miller-Chism CN, Kamble R. Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs. Annals of internal medicine. 2020 173(4):320-322. PMID: 32568574. PMCID: PMC8957217.
Al Hadidi S, Udden M. Autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia. Clinical case reports. 2020 8(6):1112-1113. PMID: 32577278. PMCID: PMC7303863.